Objectives: To investigate HLA class I allele frequencies in a Kenyan commercial sex worker (CSW) cohort, and to examine HIV-1 specific cytotoxic T lymphocyte (CTL) responses directed against epitopes derived from locally prevalent clade A virus.
Introduction
A key goal in the effort to curb the global HIV-1 pandemic is the development of a safe and effective vaccine [1] . Over 80% of new HIV infections occur in the developing world [2] , and so it is logical that vaccine development should focus on populations in these regions. Virus-specific cytotoxic T lymphocytes (CTL) are likely to be critical in prevention and control of HIV infection [3] [4] [5] , and several vaccines in development aim to induce these responses [1, 6] . The range of CTL epitopes recognized by an individual is determined by their HLA class I alleles, therefore an understanding of HLA allele distribution in target populations is important for the design and monitoring of CTL-based vaccines. HLA class I allele frequencies vary dramatically from region to region [7] , and have not been well studied in many countries most affected by the HIV-1 epidemic.
The Pumwani cohort of commercial sex workers (CSW) in Nairobi, Kenya are under intense HIV-1 infection pressure [8] . HIV-1 specific CTL are found in most highly exposed, persistently seronegative (HEPS) and HIV-infected CSW [9] [10] [11] , often restricted through HLA class I alleles that are rare in Caucasian populations [10] [11] [12] . However, some of the women do not respond to a panel of largely B clade-derived CTL epitopes [12] . This may relate to the fact that clades A and D predominate in the region [13] , or to an incomplete understanding of epitopes restricted by HLA class I alleles common in the region.
Materials and methods

Study participants
Female CSW were enrolled through a dedicated sex worker clinic based in the Pumwani district of Nairobi, Kenya [8] . This clinic provides health care services to an open CSW cohort consisting of approximately 250 women at any one time, with about 60% of attendees being HIV infected. Cohort HLA typing began in 1997, and all women presenting for annual clinic resurvey between 1997 and 1998 were enrolled in this study. Low risk Kenyan women were enrolled from a mother-child health clinic at Pumwani Maternity Hospital, Nairobi [14] . Informed consent was obtained from all study participants, and study approval was obtained from ethics boards at the Universities of Manitoba and Nairobi. HIV serostatus was tested using HIV-1 ELISA (Detect HIV, Biochem Immuno-Systems Inc., Montreal, Canada), and confirmed by Recombigen HIV-1/2 Enzyme ImmunoAssay (Cambridge Biotech Corporation, Galway, Ireland).
Molecular genotyping and sequence analysis
Molecular HLA class I genotyping was performed using PCR-single strand polymorphism (SSP) [15] . Genomic DNA from all subjects was HLA typed to medium resolution using 192 individual PCR. Genotypes that did not conform with previously described alleles were sequenced using locus-specific primers for exons 2 and 3 [16] [17] [18] [19] . Accession numbers for novel HLA alleles were obtained after submission to the European Bioinformatics Institute and the International ImMuno GeneTics database/HLA database, and novel alleles were named following the agreed policy of the WHO Nomenclature Committee [20] .
HLA-B Ã 4415 and -Cw Ã 0407 specific PCR reactions used primers (59-CCTGCGCACCGCGCTCC-39 and 59-AGCCATACATCCTCTGCCAA-39, and 59-TT TCTCCACATCCGTGTCCT-39 and 59-CTGCTCC ACCCACGGCG-39 respectively) optimized to previously described PCR conditions and parameters [15] . Their specificity was confirmed using updated highresolution phototyping.
Clade A HIV-1 peptide prediction, selection and synthesis Peptide motif prediction for novel HLA alleles was made by analogy with other HLA class I alleles [21] , and by molecular modelling using program O [22] on a Silicon Graphics workstation. Potential nonamers within the p17, p24 and Pol regions of clade A HIV [23] were then identified, based on the predicted P2 and P9 residues, and synthesized by F-moc chemistry using a Zinnser Analytical synthesizer (Advanced Chemtech, Louisville, Kentucky, USA).
Cellular assays CTL responses to candidate epitopes were screened using the modified interferon (IFN)ª ELISpot assay [12] . Peripheral blood mononuclear cells (PBMC; 5 3 10 4 /well) were incubated with either candidate peptides at 20 ìg/ml, no peptide (negative control), or 1 : 100 phytohaemagglutinin (positive control). Results were reported as Spot-Forming Units (SFU) per 1 3 10 6 PBMC, after the subtraction of background IFNª secretion. Peptide specific CTL lines were generated as described previously [24] , and were maintained in R10 medium containing interleukin-2 for 12-14 days. Standard 51 Cr release duplicate assays were performed using HLA-B Ã 4415 or Cw Ã 0407 matched and mismatched B-lymphoblastoid cell lines (BCL) labelled with 51 Cr and pulsed with 10 ìg/ml peptide, [11] unless otherwise stated.
Results
Identification of novel class I HLA alleles in the Pumwani cohort Two hundred and thirty-three female CSW from the Pumwani cohort formed the core group of this study, 141 HIV-infected (61%) and 92 HEPS (39%). All subjects were HLA class I genotyped to medium resolution (see Fig. 1a and b for HLA allele distributions). Genotyping of one subject did not conform to previously recognized PCR-SSP reaction patterns. This prompted sequencing of exons 2 and 3 of all her HLA class I alleles, identifying two novel alleles, subsequently named HLA-B Ã 4415 and HLA-Cw Ã 0407 (EMBL accession numbers AJ133471 and AJ133472, and AJ133475 and AJ133476 respectively).
PCR-SSP primers specific for HLA-B Ã 4415 were designed, and used to screen all 233 sex workers. This novel allele was present in five women (5/233; 2.1%; four HIV positive and one HEPS). HLA-B Ã 4415 was the most common HLA-B44 subtype in the cohort, making up 28% of all B Ã 44 alleles ( Fig. 1c ) and 1.1% of all HLA-B alleles overall. In addition, primers specific for HLA-Cw Ã 0407 were designed, and used to screen the subset of women with sufficient stored DNA remaining. Four women possessed this allele (4/123; 3.3%; two HIV positive and two HEPS). 
Allelic group Residue preferences are described on the updated SYPEITHI HLA motif database [21] . Where possible residues preferences are quoted as anchor or auxiliary residues. Entries followed by an asterisk have no published allele motifs and are based on epitopes published to be presented by these HLA class I alleles. %   B15  B58  B42  B53  B57  B18  B81  B49  B45  B13  B44  B14  B35  B7  B47  B51  B8  B27  B41  B65  B67  B39  B75  B19  B37  B40  B48  B50  B70  B76 Allelic group 
There was no significant association between HLA-B Ã 4415 or HLA-Cw Ã 0407 and HIV-1 susceptibility (data not shown), and these novel class I HLA alleles were present at a similar frequency in 210 low risk Kenyan women (1.9% and 3.8% respectively). HLA-B Ã 4415 and HLA-Cw Ã 0407 were found to be in linkage disequilibrium (data not shown).
Prediction of potential clade A HIV-1 epitopes presented by HLA-B Ã 4415
The peptide binding motif of HLA-B Ã 4415 was predicted by examining amino acid mismatches and similarities at residues involved in B and F binding pocket formation (Fig. 1d) . Residues forming the B pocket of HLA-B Ã 4415 correlate directly and closely with other HLA-B alleles (HLA-B Ã 4001 and -B Ã 4402, -B Ã 4403). These alleles exhibit a strong preference for acidic residues at the P2 position. Molecular modelling confirmed the viability of similar interactions by HLA-B Ã 4415. Residues involved in the F pocket of HLA-B Ã 4415 have no known HLA class I correlates [20, 25] . However molecular modelling and analogy to other similar HLA-B alleles suggests a preference for small, electrostatically neutral residues.
Using the predicted peptide motif of glutamic or aspartic acid at P2 and valine, isoleucine, leucine or alanine at the C terminus, p17, p24 and Pol sequences from clade A HIV-1 were screened for nonameric peptides potentially presented by HLA-B Ã 4415. Nineteen candidate peptides were synthesized for screening in ex vivo ELISpot assays.
A functional role for novel class I alleles in HIV-1 specific immune responses A functional role for HIV-1 specific CTL responses to the 19 predicted epitopes was investigated in a B Ã 4415 positive, HIV-1 infected member of the Pumwani cohort (ML 755) in the modified ELISpot assay. One peptide (EEKAFSPEV) produced a response . 400 SFU/1 3 10 6 PBMC above background. Subsequent 51 Cr release assays using partially HLA matched BCL targets pulsed with EEKAFSPEV confirmed HLA-B Ã 4415 restriction of a CTL line derived from this subject ( Fig. 2a-c) . Peptide-pulsed targets mismatched for HLA-B Ã 4415 were not lysed by the CTL line, confirming that the novel class I allele HLA-B Ã 4415 was able to restrict clade A HIV-1 specific CTL.
HLA Cw Ã 0407 differed from Cw Ã 0401 only in a region not associated with pocket formation, so modelling to predict novel epitopes was not performed. However, Cw Ã 0407 was demonstrated to restrict CTL against the predefined HLA-Cw Ã 0401-restricted HIV-1 gp120 epitope SFNCGGEFF (Fig. 2d) 
Discussion
The development of a safe, effective, and accessible HIV-1 vaccine offers the best chance of curbing HIV-1 in regions worst hit by the pandemic. HIV specific CTL are important in protection from HIV acquisition and disease progression, and the induction of CTL has been identified as a key component in an HIV vaccine [1] . The multi-epitope vaccine strategy aims to prime HIV-specific immunity using a string of predefined HIV-1 epitopes encoded as DNA [6] .
A paradox of HIV vaccine research is that most HIV epitopes have been characterised in ethnic groups unrepresentative of the populations worst affected by the pandemic, and infected by viral clades that are responsible for a minority of global infections [26] . Some HIV epitopes are conserved across clades and can be restricted by more than one HLA allele [26, 27] . However, cross-reaction is likely to depend on the conservation of viral sequence between clades and the similarity of HLA-peptide binding characteristics, and so this may be the exception rather than the rule [28] . Epitope cross-reactivity therefore should not be assumed, and much more work is needed to characterize epitopes and HLA distribution within affected populations. This was the rationale for examining HLA class I distribution in the Pumwani cohort of CSW, a heterogeneous population of women, most of whom have migrated to Nairobi from rural areas. Although high HIV infection pressure may bias towards HLA alleles associated with long-term non-progression and/or reduced HIV susceptibility, this cohort is likely to represent other regional high risk groups that may be the focus of future vaccine trials.
Despite the huge number of HLA class I polymorphisms already described, novel alleles are frequently identified. To find two novel alleles within these 233 individuals is not unexpected, particularly since HLA distribution in African populations has not been well studied [29] . HLA genotyping has not identified the typing discrepancy associated with HLA-B Ã 4415 in over 4000 Caucasians (M. Bunce, personal communication), and HLA-C genotyping has not identified the HLA-Cw Ã 0407 allele in a further 103 [30] . It seems likely that further HLA mapping in similar Kenyan populations will continue to reveal novel class I HLA alleles.
More surprising was the frequency with which these alleles occurred in the cohort. HLA-B44 was the tenth most common allelic group, and HLA-B Ã 4415 the most common subtype within the B44 group. HLA B Ã 4415 occurred at a similar frequency to HLA-B8 and HLA-B27, and a total of three epitopes restricted by the latter two alleles are included in the multiepitope vaccine undergoing safety trials in Kenya [6] , suggesting that the inclusion of HLA-B Ã 4415 restricted epitopes in future multi-epitope vaccine studies would be warranted. Although no association between HLA-B Ã 4415 and HIV-1 susceptibility was found, the functional relevance of HLA-B Ã 4415 was demonstrated by its ability to restrict a novel HIV-1 clade A epitope. Mapping of local HLA class I alleles and the CTL epitopes they restrict is likely to be an important component in the design of HIV vaccines for use in the areas of the world most affected by the HIV-1 pandemic. 
